In Japan, the maximal ESA dose is limited to 6,000 U epoetin-equivalent dose per week in pre-dialytic CKD patients50, which is comparable to the Taiwan NHI regulated maximal dose of 20,000 U per month. Here, EPO is linked to chronic kidney disease.